PROKIDNEY CORP (PROK)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$1.06-4.91%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · PROK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is on a run of consecutive earnings misses. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
PROK — earnings miss
Dated 2026-08-10
Results of Operations and Financial Condition. On August 10, 2026, ProKidney Corp. (the "Company") issued a press release to announce its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1. The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilit…
Why it matters: Cash was $181.6 million at Q2 end, and management said it could fund operations into mid-2027. The new deal allows share sales that may add cash but dilute holders.
Watch forA filing or company update states that share sales raised cash and the runway extends beyond mid-2027.
Also watch forCash falls sharply, the company reports a runway shorter than mid-2027, or share sales add little cash.
Why it matters: These results test if rilparencel slows kidney decline. They are also the planned basis for an accelerated approval filing.
Watch forQ2 2027 results show an eGFR slope benefit of at least 1.5 mL/min/1.73m² per year versus sham.
Also watch forResults show a benefit below 1.5 mL/min/1.73m² per year, no benefit, or a missed primary endpoint.
Why it matters: The company is losing money while it runs PROACT 1. Faster cash use could shorten its stated runway.
Worry ifThe November 9 report shows cash below $181.6 million and a runway shorter than mid-2027.
Less concerning ifThe report shows cash use slowed, with runway still reaching mid-2027 or later.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$318 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $870 loss on $10,000 · 8.7% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,315 loss on $10,000 · 63.1% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.